Market Overview

The Corporate Reputation of Pharma Companies from Skin Patient Groups, 2018 Report -


The "The
Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective
of 52 Skin Patient Groups - Skin Edition"
report has been added
to's offering

Skin patient groups are more appreciative of pharma than patient
groups in most other therapy areas - especially companies that are
demonstrating an increasing investment in skin-conditions R&D

The percentage of skin patient groups believing that the pharma
industry's corporate reputation was Excellent or Good has increased in
the last few yearsfrom 45% in 2015, to 60% in 2017. The latter figure is
significantly higher than the equivalent 2017 average among patient
groups of all therapy areas (43%). Furthermore, skin patient groups
ranked the pharmaceutical industry 1st out of nine healthcare sectors
for corporate reputation in 2017 (in 2016, they had ranked the industry

The reason for these positive views has much to do with some pharma
companies' latest R&D output in the field of dermatology. The importance
that skin patient groups place on new product development can be seen
from Chart 2, which compares the views of skin patient groups with those
of the attitudes of patient groups from 22 other specialties.

Thus, in 2017, as many as 62% of the 52 skin patient groups thought that
the pharmaceutical industry was Excellent or Good at innovation. Only
patient groups specialising in pulmonary hypertension and haemophilia
were more positive about the industry's ability to innovate in 2017.

Attitudes to pharma differ by type of skin patient group

However, attitudes among the various types of skin patient groups vary,
according to the scale of pharma investment in their particular
dermatological area. For instance, patient groups specialising in
alopecia are more negative towards pharma's R&D than those specialising
in atopic dermatitis, eczema, or psoriasis.

How can pharma improve?

The 52 skin patient groups respondent to the 2017 'Corporate Reputation
of Pharma' survey used their comments to outline some of the issues
facing new skin-treatment products:

  • The need for a more holistic approach to skin diseases and their
    treatment (involving not just medication).
  • More convenient methods of administering dosage. One suggestion was
    the creation of patient-advocacy boards, through which patients could
    give their feedback regarding the development of pill bottles, blister
    packs, aids to help opening the above items, etc.
  • High prices can form a barrier to patient uptake of skin treatments
    (particularly in countries where skin conditions such as psoriasis are
    still considered a mere cosmetic, rather than a truly medical,
    problem). Pricing is a factor that, in general, requires to be
    tackled-especially with the launch of costly biologics. Patient groups
    add, though, that their views can help establish real medical needs -
    not just those determined by clinicians and pharma - thereby
    validating access to treatment.
  • Respondent skin patient groups suggested that the pharmaceutical
    industry could better determine real patient safety concerns by
    gathering information on patient experiences. For instance, many
    patients with a skin condition would like to receive an assurance that
    a product does not contain allergens (such as perfume). Patients also
    want access to continuously-updated patient-safety information, above
    and beyond what is contained in the medicine's patient-information
  • A number of skin patient groups referred to their familiarity with the
    range of challenges faced by patients with skin conditions. Such
    in-depth expertise means that greater consultation with patient groups
    by the industry could only enhance the quality of R&D.

Report Highlights

  • Novartis was ranked overall 1st for corporate
    reputation out of 15 companies in 2017 by skin patient groups familiar
    with the company. The company was also ranked 1st for as many as nine
    of the 12 indicators of corporate reputation by skin patient groups
    familiar with it.
  • Sanofi made the biggest leap up the
    corporate-reputation rankings among skin patient groups familiar with
    it - ranking 9th in 2017, compared with 15th in 2016.

Companies Mentioned

  • Abbvie
  • Amgen
  • Astrazeneca
  • Bayer
  • Boehringer Ingelheim
  • Celgene
  • Eli Lilly
  • GSK
  • Janssen
  • Leo Pharma
  • Merck & Co
  • Novartis
  • Pfizer
  • Roche
  • Sanofi

For more information about this report visit

View Comments and Join the Discussion!